tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Angiofibroma D018322 2 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Necrobiosis Lipoidica D009335 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Churg-Strauss Syndrome D015267 2 associated lipids
Mediastinitis D008480 2 associated lipids
Hutchinson's Melanotic Freckle D018327 2 associated lipids
Fibroadenoma D018226 2 associated lipids
Mucinoses D017520 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Oliguria D009846 2 associated lipids
Castleman Disease D005871 3 associated lipids
Acneiform Eruptions D017486 3 associated lipids
Anus Diseases D001004 3 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Scleritis D015423 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Digestive System Diseases D004066 3 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Ileus D045823 3 associated lipids
Anemia, Refractory D000753 3 associated lipids
Pityriasis D010915 3 associated lipids
Uveitis, Intermediate D015867 3 associated lipids
Legionellosis D007876 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Glomerulonephritis, Membranoproliferative D015432 3 associated lipids
Failed Back Surgery Syndrome D055111 3 associated lipids
Perceptual Disorders D010468 3 associated lipids
Toxocariasis D014120 3 associated lipids
Pyoderma Gangrenosum D017511 3 associated lipids
Meningococcal Infections D008589 3 associated lipids
Fetal Hypoxia D005311 3 associated lipids
Lichen Planus D008010 3 associated lipids
Trichomonas Infections D014245 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Impetigo D007169 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Nervous System Autoimmune Disease, Experimental D020721 3 associated lipids
Epidermolysis Bullosa D004820 3 associated lipids
Paronychia D010304 3 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Facial Neoplasms D005153 3 associated lipids
Gingivitis D005891 3 associated lipids
Hemophilia B D002836 3 associated lipids
Pouchitis D019449 3 associated lipids
Cryptococcosis D003453 3 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Metalidis C et al. Expression of CYP3A5 and P-glycoprotein in renal allografts with histological signs of calcineurin inhibitor nephrotoxicity. 2011 Transplantation pmid:21544031
Peterson LB et al. A tacrolimus-related immunosuppressant with biochemical properties distinct from those of tacrolimus. 1998 Transplantation pmid:9448137
Mieles L et al. Interaction between FK506 and clotrimazole in a liver transplant recipient. 1991 Transplantation pmid:1721250
Alloway RR Mounting Clinical Evidence With Tacrolimus Generic Products. 2017 Transplantation pmid:28749820
Prókai Á et al. Calcineurin-inhibition Results in Upregulation of Local Renin and Subsequent Vascular Endothelial Growth Factor Production in Renal Collecting Ducts. 2016 Transplantation pmid:26502369
Zoppo A et al. Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. 1999 Transplantation pmid:10551656
Shihab FS et al. Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. 2009 Transplantation pmid:19202436
Asako H et al. Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. 1992 Transplantation pmid:1384191
Hirose R et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. 2000 Transplantation pmid:10670644
Takahara S et al. The in vitro immunosuppressive effect of deoxymethylspergualin in man as compared with FK506 and cyclosporine. 1992 Transplantation pmid:1373537
Kato T et al. Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. 2011 Transplantation pmid:21747275
Metcalfe SM and Richards FM Cyclosporine, FK506, and rapamycin. Some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. 1990 Transplantation pmid:1691537
Sindhi R et al. Sirolimus for rescue and primary immunosuppression in transplanted children receiving tacrolimus. 2001 Transplantation pmid:11571449
Timmermann W et al. Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. 1999 Transplantation pmid:10401762
Fujimura Y and Owen RL Tacrolimus (FK506) and cyclosporine reduce the uptake and transport of particles into rabbit Peyer's patches. 2002 Transplantation pmid:11965030
Gallon L et al. Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. 2015 Transplantation pmid:25905982
Hricik DE et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. 2007 Transplantation pmid:17297401
Kaufman DB et al. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. 1999 Transplantation pmid:10071032
Bozorgzadeh A et al. Impact of hepatitis C viral infection in primary cadaveric liver allograft versus primary living-donor allograft in 100 consecutive liver transplant recipients receiving tacrolimus. 2004 Transplantation pmid:15087773
Diem HV et al. Pediatric liver transplantation for biliary atresia: results of primary grafts in 328 recipients. 2003 Transplantation pmid:12777858
Luan FL et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. 2002 Transplantation pmid:12042641
Smets F et al. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease. 2002 Transplantation pmid:12042647
Merkle M et al. The effect of sevelamer on tacrolimus target levels. 2005 Transplantation pmid:16177649
Couzi L et al. Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. 2008 Transplantation pmid:18946343
Andoh TF et al. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. 1994 Transplantation pmid:7509514
Demmers MW et al. Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. 2014 Transplantation pmid:24157471
Imado T et al. Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. 2004 Transplantation pmid:14966413
Woodle ES et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. 1996 Transplantation pmid:8830821
Furlan V et al. Interactions between FK506 and rifampicin or erythromycin in pediatric liver recipients. 1995 Transplantation pmid:7537398
Akst LM et al. Induction of tolerance in a rat model of laryngeal transplantation. 2003 Transplantation pmid:14688529
Mañez R et al. Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. 1995 Transplantation pmid:7537400
Pacifico L et al. Tacrolimus and food allergy. 2003 Transplantation pmid:14688538
Sulanc E et al. New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. 2005 Transplantation pmid:16249743
Vyas S et al. Outcome of twin pregnancy in a renal transplant recipient treated with tacrolimus. 1999 Transplantation pmid:10030303
Muthukkumar S et al. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. 1995 Transplantation pmid:7544036
Boots JM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. 2002 Transplantation pmid:12499885
Mikhalski D et al. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression. 2008 Transplantation pmid:18401260
Metcalfe S and Milner J Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. 1991 Transplantation pmid:1710844
Paolillo JA et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus-based immunosuppression. 2001 Transplantation pmid:11213069
Molmenti EP et al. Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. 2001 Transplantation pmid:11213072
Min SI et al. CYP3A5 *1 allele: impacts on early acute rejection and graft function in tacrolimus-based renal transplant recipients. 2010 Transplantation pmid:21076384
Ciancio G et al. A randomized pilot study of donor stem cell infusion in living-related kidney transplant recipients receiving alemtuzumab. 2013 Transplantation pmid:23903014
Jain AB et al. Capillary blood versus arterial or venous blood for tacrolimus monitoring in liver transplantation. 1995 Transplantation pmid:7545836
Vincenti F et al. One-year follow-up of an open-label trial of FK506 for primary kidney transplantation. A report of the U.S. Multicenter FK506 Kidney Transplant Group. 1996 Transplantation pmid:8669100
Lerut J et al. Anti-CD2 monoclonal antibody and tacrolimus in adult liver transplantation. 2005 Transplantation pmid:16314784
Komori K et al. The role of graft and host accommodation in a hamster-to-rat cardiac transplantation model. 2008 Transplantation pmid:18192920
Bolley R et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. 2002 Transplantation pmid:11923712
Gruber SA and Doshi MD Conversion to sirolimus in African American renal allograft recipients undergoing early steroid withdrawal: intermediate-term risks and benefits. 2010 Transplantation pmid:20440195
Burger CI et al. Case report: drug interaction between tacrolimus and amiodarone with QT prolongation. 2010 Transplantation pmid:20440199
Mayer AD et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. 1997 Transplantation pmid:9275110